News

A large-scale DNA analysis in different tissues revealed an association between scleroderma and groups of genes driving well-known inflammation pathways. This approach helps explain the complex interplay between the diverse genes associated with scleroderma development. It also shows potential to lead to targeted and effective therapies, the investigators…

A specific variant in the STAT4 gene protects people with scleroderma against the development of interstitial lung disease (ILD), a new study in patients of European descent suggests. However, more and larger studies are needed to identify the genetic risk factors that make some people with scleroderma…

Early detection of bowel perforation in scleroderma patients who are experiencing abdominal symptoms may be lifesaving, according to a case report. Researchers emphasize that it is essential clinicians be aware of the risk and possible severe consequences of bowel perforation in these patients. Effective therapies halting tissue scarring (fibrosis) are required…

The U.S. Food and Drug Administration (FDA) has cleared an application from Emerald Health Pharmaceuticals that paves the way to begin a Phase 2 clinical trial testing EHP-101 in people with scleroderma. EHP-101 is an oral therapy based on cannabidiol (CBD), one of the main components of cannabis and…

The combination of three imaging techniques can provide a better understanding of structural and functional skin changes in the fingers, leading to an earlier and more accurate diagnosis of scleroderma, a new study suggests. The study, “Combining optical coherence tomography with magnetic resonance angiography and Doppler ultrasonography for…

Researchers have zeroed in on autoantibodies that may be linked to distinct human leukocyte antigen (HLA) genes and environmental factors, something that could help explain the high variability of scleroderma and why some disease forms are more prevalent in African-Americans. The study, “HLA and autoantibodies define scleroderma subtypes…

Using a new stem cell-based model, researchers have discovered a molecule that can reverse tissue damage caused by inflammation and fibrosis (scarring), a study shows. The study, “Modeling Progressive Fibrosis with Pluripotent Stem Cells Identifies an Anti-fibrotic Small Molecule,” was published in Cell Reports. Fibrotic diseases,…

Intravenous antibodies can be used as add-on therapy to reduce the dosage of corticosteroids and achieve disease remission in people with scleroderma-associated myopathy (SScAM), or muscle disease, a study suggests. The study, “Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients,”…

A new collaboration between Servier Pharmaceuticals and University College London (UCL) seeks to speed the discovery of new therapies for immune-inflammatory disorders such as scleroderma. The initial two-year agreement calls for Servier to share scientific knowledge with UCL researchers who are investigating how scleroderma develops, as well as…

The Scleroderma Foundation is among the recipients of nearly $200,000 in awards through the 2020 RARE Patient Impact Grant program of Global Genes, a rare disease patient advocacy organization. Twenty foundations will receive funding to improve the lives of rare disease patients through education, resources, and other support.